Seeking Alpha

Seeking Alpha Portfolio App for iPad

924 people get HSP articles and Market Currents by email alert.

Get email alerts on HSP »

HSP

Hospira, Inc.

6/19/2013, 7:19 AM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Sunday, June 16, 10:00 AM My bid for Berkshire (BRK.A, BRK.B) would be about 20% lower than the current price, says Michael Price in an outstanding presentation on the process of value investing. GE has 1K tax lawyers figuring out taxes in 100 different countries, says Price, but Berkshire (also operating in 100 countries) has 20 people in the entire home office ... "I don't know how that works?" Unlike a lot of large companies, Berkshire gives little light on its pension liabilities. "There are lots of questions that will come up in the next 5 years there." The video also sheds a good deal more color on two Price longs: Hospira (HSP) and Hess (HES). 20 Comments [Quick Ideas]
Monday, June 3, 3:06 PM Hospira (HSP +1.2%) says results from a post-marketing study of the company's European biosimilar epoetin, Retacrit, met its primary endpoint in the management of chemotherapy-induced anemia in adult patients with solid tumors, lymphomas and myelomas, regardless of chemotherapy cycle.. Comment! [Healthcare, On the Move]
Thursday, May 30, 8:52 AM Hospira's (HSP) quality control problems continue, with the FDA sending the company a warning latter about problems at its facility in the southern Indian state of Tamil Nadu. Hospira has faced several regulatory issues since 2010, and earlier this year, it withdrew its 2013 guidance after the FDA blocked the import of some of its products. 1 Comment [Healthcare]
Wednesday, May 22, 1:35 PM Citing an FDA warning letter and the company's revised FY13 guidance among other factors, Moody's puts Hospira's (HSP -0.8%) long-term debt rating on review for downgrade. The ratings agency says "cash payouts associated with [HSP's new medical device] strategy, remediation costs, and the potential for lost sales once its branded injectible sedative, Precedex, loses patent protection" could hurt liquidity and tighten credit metrics. Comment! [Healthcare]
Tuesday, May 14, 8:48 AM Presenting at the London Value Conference, Michael Price pitches Hospira (HSP) - a stock the growth investors have unloaded to the value guys after the FDA shut down one of its largest plants. He expects the company to have completely recovered within 2 years. He's also bullish on HESS, trading at a 50% discount to intrinsic value amid its proxy fight with Elliot - the outcome of which will see 4-5 new directors, and a split or even buyout of the company. A bearish idea: Berkshire Hathaway (BRK.A, BRK.B) is 20% overvalued. 1 Comment [Quick Ideas]
Thursday, May 9, 1:13 PM Hospira (HSP +2%) sues B. Braun for allegedly infringing upon the former's patents for drug-infusion pump technology. HSP is seeking unspecified damages for lost profits and legal fees. (Bloomberg) Comment! [Healthcare, On the Move]
Wednesday, May 1, 7:51 AM Hospira (HSP): Q1 EPS of $0.52 beats by $0.08. Revenue of $988.3M beats by $8.97M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, May 1, 12:05 AM Notable earnings before Wednesday’ s open: AB, ADT, AFAM, AFSI, AGN, AH, AMT, ARW, AVA, CCJ, CHK, CLH, CLX, CMCSA, CVH, CVS, DLPH, DVN, ENR, EXAS, EXC,GRMN, GWR, H, HSP, HUM, ICE, IPGP, IQNT, IRM, JRCC, KCG, KFN, MA, MKL, MRK, NVO, PDCE, PKD, POR, PSX, RDC, RDN, SEE, SPW, TLM, TWX, VG, VIAB, VPHM Comment! [Earnings]
Tuesday, April 30, 5:30 PM Notable earnings before Wednesday’ s open: AB, ADT, AFAM, AFSI, AGN, AH, AMT, ARW, AVA, CCJ, CHK, CLH, CLX, CMCSA, CVH, CVS, DLPH, DVN, ENR, EXAS, EXC,GRMN, GWR, H, HSP, HUM, ICE, IPGP, IQNT, IRM, JRCC, KCG, KFN, MA, MKL, MRK, NVO, PDCE, PKD, POR, PSX, RDC, RDN, SEE, SPW, TLM, TWX, VG, VIAB, VPHM Comment! [Earnings]
Monday, March 18, 2:10 PM Hospira (HSP -1.8%) says the FDA's granted pediatric exclusivity for it's alpha-2 agonist Precedex injection. The decision extends generic exculsivity by a period of six months after patent expiry. Comment! [Healthcare, On the Move]
Friday, March 1, 12:39 PM Hospira (HSP -0.1%) slips into the red on reports that Glaxo SmithKline (GSK +0.2%) is suing the company over the quality of its flu vaccine supply. Comment! [Healthcare]
Thursday, February 14, 7:32 PM Shares of Hospira (HSP) took a hit today after the maker of intravenous pumps says the FDA has expanded an import ban on several of its products made in a Costa Rica plant. Due to the ban - and just a day after the company reported Q4 earnings - it now says it's withdrawing FY13 guidance, adding it could see sales drop by $50M to $100M, and earnings fall by $0.05 to $0.15 a share. 1 Comment [Healthcare]
Thursday, February 14, 5:46 PM After-hours top gainers, as of 5:15 p.m.: QLIK +14%. HLF +13%. DTLK +12%. TFM +9%. HSP +9%.
After-hours top losers: LOGM -22%. ACTV -10%. A -8%. BGS -7%. ASGN -5%. 1 Comment [On the Move]
Wednesday, February 13, 2:14 PM Hospira (HSP -5.7%) takes a hit today after posting better-than-expected Q4 results, but issuing a disappointing outlook for FY13. Net earnings swung to a profit amid stronger sales of its specialty drugs and the impact of a major write-down in the prior-year period, but the company warns that FY13 will be burdened by ongoing heavy costs to resolve regulatory concerns over manufacturing at some of its plants. It now expects to earn between $2.05 to $2.20 on net sales growth of 1% to 3%, below estimates of $2.31 on revenue growth of 4%. 1 Comment [Healthcare, Earnings, On the Move]
Wednesday, February 13, 7:44 AM Hospira (HSP): Q4 EPS of $0.55 beats by $0.01. Revenue of $1.1B beats by $0.06B. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, February 13, 12:05 AM Notable earnings before Wednesday’s open: ASPS, AVEO, CPN, DE, DF, DPS, DUK, EZCH, FBN, H, HSP, LO, PES, PRLB, TLM, TRI, VG, WCG, WFR 1 Comment [Earnings]